Product Name: IRAK4 (439-455) pT342+pT345+pS346+pT351+pT352+pY354
Product Number: PE-04AVI85
Peptide Name: IRAK4 (439-455) pT342+pT345+pS346+pT351+pT352+pY354
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T342, T345 and S346 phosphorylation stimulate phosphotransferase activity. T351, T352 and Y354 phosphorylations are predicted to be inhibitory to phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: FAQ-pT-VM-pT-pS-RIVG-pT-pT-A-pY-M
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 2572.5 Da
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: IRAK4 is a protein-serine/threonine kinase of the TKL group and IRAK family .It plays a critical role in initiating innate immune response against foreign pathogens. It is involved in Toll-like receptor (TLR) and IL-1R signalling pathways, and is rapidly recruited by MYD88 to the receptor-signalling complex upon TLR activation to form the Myddosome together with IRAK2. It phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. It phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. IRAK4 phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. It phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation.